Eli Lilly Australia has confirmed that its diabetes medicine MOUNJARO (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme for type 2 diabetes, despite receiving a positive recommendation from the Pharmaceutical Benefits Advisory Committee. …
Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation
April 28, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News